SEC Filings
Form 20-F
WUXI PHARMATECH (CAYMAN) INC. filed this Form 20-F on 04/17/2013
Document Outline
Entire Document (6575.8 KB)
Subdocument 1 - 20-F - FORM 20-F
Page 1 - UNITED STATES
Page 2 - WuXi PharmaTech (Cayman) Inc.
Page 3 - INTRODUCTION
Page 4 - FORWARD-LOOKING STATEMENTS
Page 5 - PART I
Page 6 - N/A
Page 7 - Exchange Rate Information
Page 8 - Source: Exchange rates supplied by the Federal Reserve Bank of New York for 2008 and by the H.10 Sta
Page 9 - A limited number of our customers have accounted for, and are expected to continue to account for, a
Page 10 - New technologies or methodologies may be developed, validated and used in the global pharmaceutical,
Page 11 - We may be unable to expand our capacity and scale up our operations within the timeframe or budgeted
Page 12 - We may fail to effectively develop and market new services, which may harm our growth opportunities
Page 13 - The global economic uncertainty adversely affected, and could continue to adversely affect, our busi
Page 14 - Recent litigation and negative publicity surrounding China-based companies listed in the United Stat
Page 15 - If we fail to protect our customers intellectual property rights, we may be subject to liability for
Page 16 - Any failure to comply with existing regulations and industry standards could harm our reputation and
Page 17 - Negative attention from special interest groups may impair our ability to operate our business effic
Page 18 - Restrictions on our operations contained in agreements relating to bank loans may limit how we condu
Page 19 - Under China s EIT Law, we may be classified as a resident enterprise of China. This classification c
Page 20 - The discontinuation of any of the financial incentives currently available to us in the PRC could ad
Page 21 - Fluctuations in exchange rates have resulted in, and are expected to continue to result in, foreign-
Page 22 - PRC regulations relating to offshore investment activities by PRC residents may increase the adminis
Page 23 - Restrictions on currency exchange may limit our ability to utilize our revenues effectively.
Page 24 - Proceedings instituted recently by the SEC against five PRC-based accounting firms, including our in
Page 25 - The trading prices of our ADSs have been, and are likely to continue to be, volatile, which could re
Page 26 - Holders of ADSs may not receive distributions on our ordinary shares or any value for them if it is
Page 27 - We are a Cayman Islands company. Because judicial precedent regarding the rights of shareholders is
Page 28 - We may need additional capital that we may be unable to obtain in a timely manner on acceptable term
Page 29 - B. Business Overview
Page 30 - in vitro
Page 31 - A highly educated and trained workforce.
Page 32 - Laboratory Services Segment
Page 33 - Analytical Development.
Page 34 - Development.
Page 35 - Manufacturing Services Segment
Page 36 - Customers
Page 37 - Intellectual Property (IP)
Page 38 - Insurance
Page 39 - Blood and Reagent Import/Export
Page 40 - PRC Patent Law
Page 41 - Regulation of Foreign Exchange in Certain Onshore and Offshore Transactions
Page 42 - Regulations on Employee Stock Incentive Plans
Page 43 - Company Law
Page 44 - C. Organizational Structure
Page 45 - N/A
Page 46 - N/A
Page 47 - D. Property, Plant and Equipment
Page 48 - A. Operating Results
Page 49 - Components of Revenue and Expenses
Page 50 - Laboratory Services Segment
Page 51 - Gross Profit and Gross Margin
Page 52 - Operating Income and Operating Margin
Page 53 - N/A
Page 54 - Results of Operations
Page 55 - Laboratory Services Segment Net Revenues
Page 56 - Gross Profit and Gross Margin
Page 57 - Laboratory Services Segment Net Revenues
Page 58 - Gross Profit and Gross Margin
Page 59 - Business Combinations
Page 60 - Revenue Recognition
Page 61 - B. Liquidity and Capital Resources
Page 62 - Investing Activities
Page 63 - D. Trend Information
Page 64 - Dr. Ge Li
Page 65 - Alexander Fowkes
Page 66 - 2007 Employee Share Incentive Plan
Page 67 - C. Board Practices
Page 68 - Board Committees
Page 69 - Compensation Committee
Page 70 - Corporate Governance
Page 71 - N/A
Page 72 - A. Major Shareholders
Page 73 - Employment Agreements
Page 74 - B. Significant Changes
Page 75 - F. Expenses of the Issue
Page 76 - Regulation of Foreign Exchange in Certain Onshore and Offshore Transactions
Page 77 - E. Taxation
Page 78 - Prospective purchasers are urged to consult their own tax advisor concerning the particular U.S. fed
Page 79 - Sales and Other Dispositions of ADSs or Ordinary Shares
Page 80 - U.S. Information Reporting and Backup Withholding Rules
Page 81 - I. Subsidiaries Information
Page 82 - Interest-Rate Risk
Page 83 - D. American Depositary Shares
Page 84 - Fees Payable by the Depositary to the Issuer
Page 85 - PART II
Page 86 - de minimis
Page 87 - N/A
Page 88 - PART III
Page 89 - N/A
Page 90 - SIGNATURE
Page 91 - WUXI PHARMATECH (CAYMAN) INC.
Page 92 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 93 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 94 - WUXI PHARMATECH (CAYMAN) INC.
Page 95 - WUXI PHARMATECH (CAYMAN) INC.
Page 96 - WUXI PHARMATECH (CAYMAN) INC.
Page 97 - WUXI PHARMATECH (CAYMAN) INC.
Page 98 - WUXI PHARMATECH (CAYMAN) INC.
Page 99 - WUXI PHARMATECH (CAYMAN) INC.
Page 100 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Page 101 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 102 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 103 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 104 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 105 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 106 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 107 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 108 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 109 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 110 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 111 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 112 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 113 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 114 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 115 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 116 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 117 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 118 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 119 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 120 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 121 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 122 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 123 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 124 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 125 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 126 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 127 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 128 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 129 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 130 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 131 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 132 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 133 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 134 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 135 - NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Page 136 - SCHEDULE 1 WUXI PHARMATECH (CAYMAN) INC.
Page 137 - SCHEDULE 1 WUXI PHARMATECH (CAYMAN) INC.
Page 138 - SCHEDULE 1 WUXI PHARMATECH (CAYMAN) INC.
Page 139 - SCHEDULE 1 WUXI PHARMATECH (CAYMAN) INC.
Page 140 - SCHEDULE 1 WUXI PHARMATECH (CAYMAN) INC.
Subdocument 2 - EX-8.1 - EX-8.1
Page 1 - Exhibit 8.1
Page 2 - N/A
Subdocument 3 - EX-12.1 - EX-12.1
Page 1 - Exhibit 12.1
Subdocument 4 - EX-12.2 - EX-12.2
Page 1 - Exhibit 12.2
Subdocument 5 - EX-13.1 - EX-13.1
Page 1 - Exhibit 13.1
Subdocument 6 - EX-13.2 - EX-13.2
Page 1 - Exhibit 13.2
Subdocument 7 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Subdocument 8 - EX-23.2 - EX-23.2
Page 1 - Exhibit 23.2
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer